Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Director Sanjay Shrestha of Health In Tech received a grant of 128,474 restricted shares of Class A Common Stock at $0.62 per share on June 23, 2025, as reported in this Form 4 filing.
Key details of the stock grant:
- Shares were granted under the Health in Tech Equity Incentive Plan
- Vesting conditions include: - Full vesting after one year of service from April 8, 2025, or - Partial vesting at first shareholders' meeting based on service period ratio
- Direct ownership form of securities
- Vesting subject to continuous service requirement
This equity grant appears to be part of director compensation and aligns the director's interests with shareholders through a one-year vesting schedule.
Director Chike Umemezia of Health In Tech received a grant of 128,474 restricted shares of Class A Common Stock on June 23, 2025, at a price of $0.62 per share under the company's Equity Incentive Plan.
The restricted shares have specific vesting conditions:
- Full vesting after one year of service from December 23, 2024, or
- Partial vesting at the first shareholders' meeting based on a pro-rata calculation of service time (up to 12 months) from December 23, 2024
The grant represents a direct ownership position and requires continuous service through the vesting date. This equity compensation aligns the director's interests with shareholders and serves as a retention mechanism through the vesting schedule.